- Aug 7
- 8 min read
Key Takeaways |
One month after infusion, this patient reached complete metabolic remission (CMR) — confirmed by PET-CT, with no detectable tumor activity — following a combined autologous stem cell transplant and CD19 CAR-T cell infusion. |
The disease had already outlasted years of standard treatment. Diagnosed with high-risk follicular lymphoma in 2020, it transformed into the more aggressive diffuse large B-cell lymphoma (DLBCL) in 2022 after multiple lines of chemotherapy and targeted therapy failed to control it. |
The treatment combined two advanced procedures in a single, closely sequenced course — stem cell collection, CAR-T cell manufacturing, pretreatment chemotherapy, stem cell reinfusion, and CAR-T infusion — completed over roughly five months, with the patient discharged just three weeks after the CAR-T infusion. |
The hospital's hematology program has since expanded this approach to additional blood cancers, including acute lymphoblastic leukemia — part of a broader pattern of CAR-T access spreading beyond China's largest metro hubs. |
Introduction
Follicular lymphoma is usually a slow-moving cancer, but in a meaningful share of patients it eventually transforms into a much more aggressive disease — diffuse large B-cell lymphoma — that behaves nothing like the original diagnosis and responds poorly to standard chemotherapy. Patients who reach this point, especially after several lines of treatment have already failed, often have few remaining options and a difficult prognosis.
This case follows a 41-year-old patient whose follicular lymphoma took exactly that path: two years of treatment, a transformation to DLBCL, and a disease that kept advancing despite repeated chemotherapy and targeted-drug combinations. By the time his hematology team proposed CAR-T therapy, a large abdominal mass was pressing on nearby organs, causing pain severe enough to make walking difficult.
What makes the case notable is not just the outcome, but the treatment pathway: a combined autologous stem cell transplant and CD19 CAR-T cell infusion, planned and delivered by a single hematology team over several months. For readers who want the fuller picture of how CAR-T therapy works, who qualifies, and what the process looks like for international patients, our complete 2026 guide to CAR-T treatment in China covers the landscape this case sits within.
The Patient's Situation Before Treatment
Patient: Mr. Liu (pseudonym), age 41 at the time of treatment
Original diagnosis: Follicular lymphoma, grade 3b, stage IVA, classified high-risk — diagnosed in January 2020
Disease course: Initial immune-targeted chemotherapy brought temporary relief, but the disease progressed and control became increasingly difficult over the following two years
The turning point: A biopsy in February 2022 showed the follicular lymphoma had transformed into diffuse large B-cell lymphoma — a more aggressive subtype with a distinct treatment profile. A further round of combination chemotherapy and targeted therapy still failed to stop progression
Complicating factors: By this stage, the patient also had a right lower-limb venous thrombosis and kidney-related complications — comorbidities that made an already high-risk CAR-T candidate more complex to manage
Why standard options had run out: A large abdominal tumor mass was compressing surrounding organs, causing significant abdominal and leg pain and impairing his ability to walk. With multiple prior lines of therapy exhausted and the disease still advancing, his medical team and family agreed to pursue CAR-T cell therapy combined with stem cell transplantation as the next option
The Medical Team & the Treatment/Institution
The patient was treated at a top-ranked 3A-grade academic hospital in Shenyang, in China's Liaoning Province — one of the most established blood-disease treatment centers in Northeast China, with a hematology program built over more than five decades and a long-running autologous stem cell transplant service for lymphoma dating back to the early 1990s.
The case was led by Prof. Han Meiling (pseudonym), Director of the hospital's hematology department, working alongside Dr. Zhou Bin (pseudonym), associate professor, Dr. Wei Chen (pseudonym), associate professor, and Nurse Lin Fang (pseudonym), who coordinated day-to-day care through the treatment course. Given the complexity of the case — a heavily pretreated, transformed lymphoma layered with thrombosis and kidney complications — the team consulted extensively with domestic and international CAR-T specialists and colleagues across the hospital's blood transfusion, radiotherapy, urology, vascular surgery, and critical care departments before proceeding.
The CAR-T product used was relmacabtagene autoleucel (relma-cel), marketed in China as Carteyva — an anti-CD19 chimeric antigen receptor T-cell therapy that was approved by China's National Medical Products Administration (NMPA) in September 2021 for relapsed or refractory large B-cell lymphoma, with its approved use later extended to relapsed/refractory follicular lymphoma. Like other CD19-directed CAR-T products, it works by re-engineering a patient's own T-cells to recognize and destroy CD19-positive lymphoma cells, then reinfusing them as a single, personalized "living drug." What made this case unusual for the region was the sequencing: the team combined the CAR-T infusion with an autologous stem cell transplant, a pairing that, according to the original hospital report, had not previously been carried out at this hospital, or by any hematology team in the three northeastern provinces.
Treatment Timeline
Date/Stage | What Happened |
January 2020 | Diagnosed with follicular lymphoma, grade 3b, stage IVA, high-risk |
February 2022 | Biopsy confirms transformation to diffuse large B-cell lymphoma; further chemotherapy and targeted therapy fail to control disease |
February–March 2022 | Autologous peripheral blood stem cells collected following chemotherapy |
April 2022 | Peripheral blood cells collected via leukapheresis to manufacture autologous CAR-T cells |
May 2022 | CAR-T cell product manufactured and cleared quality inspection for release |
Late May 2022 | Pretreatment (lymphodepleting) chemotherapy administered, followed by reinfusion of the autologous stem cells |
June 1, 2022 | Autologous CD19 CAR-T cell infusion administered |
June 15, 2022 | Transferred from isolation ward to general ward |
June 20, 2022 | Discharged from hospital in stable condition |
July 1, 2022 | First efficacy evaluation: PET-CT shows complete metabolic remission (CMR), with the tumor no longer detectable |
The treating team described the result as a turning point for a patient who had run through nearly every standard option, noting that long-term efficacy monitoring would continue beyond the initial post-infusion evaluation.
What This Case Reflects About CAR-T Access in China
This case is also a marker of how far CAR-T access has spread within China. For years, advanced cellular therapies for blood cancers were concentrated almost entirely in Beijing, Shanghai, and a handful of other major hubs, which meant patients from other regions often had to travel far from home for treatment and follow-up. This hospital's hematology department launched the first CAR-T program in Liaoning Province in 2021, and has since expanded its use beyond lymphoma and myeloma to include acute lymphoblastic leukemia — part of a broader national trend of CAR-T infrastructure decentralizing to more regional academic centers. For readers comparing today's approved options, our comparison of FDA-approved CAR-T products breaks down how relma-cel and other CD19-directed therapies stack up by indication and cost.
FAQ
Is CAR-T therapy an option after follicular lymphoma transforms into DLBCL?
Yes. CD19-directed CAR-T products approved in China, including relma-cel, are indicated for relapsed or refractory large B-cell lymphoma, which includes cases where follicular lymphoma has transformed into a more aggressive subtype after standard treatments have failed.
What does "complete metabolic remission" mean on a PET-CT scan?
It means the scan shows no remaining areas of abnormal metabolic activity consistent with active tumor tissue. It is a strong early indicator of response, but doctors typically continue monitoring for months or years to confirm the remission is durable.
Why would a patient need both a stem cell transplant and CAR-T therapy?
The two procedures serve different purposes and are sometimes combined for heavily pretreated patients: the stem cell transplant helps restore healthy blood cell production after intensive chemotherapy, while the CAR-T infusion targets the remaining cancer cells directly. Combining them is more complex to plan and manage, which is why it is typically reserved for specialized centers with experience in both procedures.
How much does CAR-T therapy cost for lymphoma patients in China?
Costs vary by hospital, product, and package inclusions. Our 2026 CAR-T cost breakdown walks through current pricing for international patients.
Are comorbidities like blood clots or kidney issues a barrier to CAR-T eligibility?
Not necessarily, but they add complexity. As in this case, hospitals with experienced multidisciplinary teams can often manage patients with additional health complications, though eligibility is always assessed on a case-by-case basis through a full medical evaluation.
Is CAR-T therapy only available at major hospitals in Beijing or Shanghai?
No — while those cities remain major hubs, CAR-T programs have expanded to academic hospitals in other regions of China over the past several years, improving access for patients outside the largest metro areas.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — an international medical concierge company headquartered in New York, specialized in securing premium second opinions from top US hospitals and specialists. With over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized as one of the leading patient access services across North America and the Asia-Pacific, bringing the same standard of expert care coordination to every patient we serve.
Disclaimer
This article is for informational purposes only and does not constitute medical or financial advice. Please confirm all treatment-specific details with a qualified oncologist or a ChinaCureLink coordinator before making any treatment decisions.
References
First combined CAR-T and autologous stem cell transplant reported for relapsed follicular lymphoma patient in Northeast China. Hospital press release, republished via The Paper, July 8, 2022. https://m.thepaper.cn/baijiahao_18926646
JW Therapeutics. "JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China." PR Newswire, September 6, 2021. https://www.prnewswire.com/in/news-releases/jw-therapeutics-announces-nmpa-approval-of-relmacabtagene-autoleucel-injection-in-china-837651458.html
Zhang X, et al. "Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults," noting relma-cel's approved indications for relapsed/refractory large B-cell lymphoma and follicular lymphoma in China. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC12917526/
"CAR-T Immunotherapy in China: A 2026 Guide for International Patients." China CureLink. https://www.chinacurelink.com/post/car-t-immunotherapy-in-china-a-2026-guide-for-international-patients
"FDA Approved CAR-T Cell Therapy in 2026: Products, Advantages, and Costs Compared." China CureLink. https://www.chinacurelink.com/post/fda-approved-car-t-cell-therapy-in-2026-products-advantages-and-costs-compared
"CAR-T Cell Therapy Price 2026: A Global Cost Breakdown for Patients and Families." China CureLink. https://www.chinacurelink.com/post/car-t-cell-therapy-price-2026-a-global-cost-breakdown
Comments